5-HT2A receptor

5-HT2A receptor
DrLee · CC0 · source
Name	5-HT2A receptor
Gene	HTR2A
Family	G protein-coupled receptor
Ligand	Serotonin
Location	Central nervous system

5-HT2A receptor The 5-HT2A receptor is a G protein-coupled receptor encoded by the HTR2A gene, central to serotonergic neurotransmission. It is a primary target for classical psychedelics, atypical antipsychotics, and various psychoactive compounds, and it influences cognition, perception, and mood in humans. Research on the receptor involves molecular genetics, pharmacology, and clinical studies spanning institutions such as National Institutes of Health, Harvard University, and University of Oxford.

Structure and molecular biology

The 5-HT2A receptor is a seven-transmembrane domain receptor belonging to the rhodopsin-like GPCR superfamily, with structural insights informed by crystallography and computational modeling performed at centers like Massachusetts Institute of Technology, Stanford University, and Imperial College London. The HTR2A gene locus on chromosome 13q14-q21 has been studied in cohorts from Boston and Cambridge, with single nucleotide polymorphisms characterized in studies executed by teams at University College London and Karolinska Institute. Protein post-translational modifications such as phosphorylation and palmitoylation have been mapped using mass spectrometry techniques developed at Max Planck Society laboratories and applied by groups at Johns Hopkins University. Mutagenesis experiments guided by structural models from European Molecular Biology Laboratory researchers have clarified ligand binding pockets and key residues that determine agonist versus antagonist efficacy.

Expression and distribution

5-HT2A receptor expression is prominent in cortical regions implicated in higher cognition, revealed by autoradiography and in situ hybridization protocols standardized at National Institute of Mental Health and implemented by researchers at Columbia University and Yale University. High densities are reported in prefrontal cortex, claustrum, and layer V pyramidal neurons in primate studies conducted at Primate Research Centers affiliated with University of California, Davis and Emory University. Peripheral expression in platelets and vascular smooth muscle has been documented in clinical laboratories at Mayo Clinic and Cleveland Clinic. Developmental expression patterns were characterized in investigations funded by Wellcome Trust and executed at University of Edinburgh and Monash University.

Pharmacology and ligands

Pharmacological characterization of 5-HT2A includes classical agonists like serotonin and psilocybin, partial agonists such as lisuride, and antagonists including clozapine and ketanserin; these compounds have been studied in pharmacology programs at Pfizer, AstraZeneca, and Roche. Psychedelic ligands such as LSD were central to early psychopharmacology at Sandoz Laboratories and later reinvestigated in clinical trials at Imperial College London and Johns Hopkins University. Radioligands for PET imaging, developed in collaborations between National Institutes of Health and UCL, have enabled in vivo occupancy studies across cohorts at Karolinska Institutet and Duke University. Allosteric modulators and biased agonists are active areas pursued by teams at GlaxoSmithKline and academic groups at University of Cambridge.

Physiological and behavioral functions

Activation of 5-HT2A receptors modulates cortical excitability, sensory processing, and synaptic plasticity, phenomena explored in landmark studies at Salk Institute and Cold Spring Harbor Laboratory. Behavioral paradigms showing effects on perception and cognition were developed in laboratories at Princeton University and University of California, Berkeley, linking receptor activity to altered states reported in historical clinical research at Good Friday Experiment-era institutions and modern trials at NYU Langone Health. The receptor contributes to vascular tone and platelet aggregation as investigated in cardiovascular units at Johns Hopkins Hospital and Mount Sinai Hospital.

Role in psychiatric disorders and therapeutics

Dysregulation of 5-HT2A signaling is implicated in schizophrenia, depression, and PTSD; clinical trials assessing receptor-targeted compounds have been conducted at Mayo Clinic, Massachusetts General Hospital, and McLean Hospital. Atypical antipsychotics with 5-HT2A antagonism, developed by companies such as Janssen Pharmaceuticals and Eli Lilly and Company, shaped treatment paradigms tested in multicenter studies coordinated by World Health Organization-affiliated networks. Psychedelic-assisted therapies harnessing 5-HT2A agonists have advanced through trials at Johns Hopkins University, Imperial College London, and MAPS-sponsored studies, prompting regulatory review by bodies including Food and Drug Administration and European Medicines Agency.

Signaling pathways and intracellular mechanisms

Upon agonist binding, 5-HT2A receptors couple primarily to Gq/11 proteins to activate phospholipase C, inositol trisphosphate, and diacylglycerol pathways, signaling modules elucidated by biochemical research at Rockefeller University and Weill Cornell Medicine. Beta-arrestin recruitment and receptor internalization dynamics have been characterized using live-cell imaging technologies pioneered at Harvard Medical School and instrumentation from Zeiss. Cross-talk with glutamatergic NMDA receptor signaling, documented in synaptic physiology studies at Cold Spring Harbor Laboratory and Riken, underpins effects on synaptic plasticity and gene transcription mediated via ERK/MAPK cascades studied at European Molecular Biology Laboratory.

Research tools and experimental methods

Tools for studying 5-HT2A include selective pharmacological agents, radioligands for PET developed by collaborations between National Institute on Drug Abuse and University College London, CRISPR/Cas9 gene editing workflows applied at Broad Institute, and transgenic mouse lines generated at facilities like Jackson Laboratory. Electrophysiological recordings and optogenetic manipulations performed at MIT McGovern Institute and Stanford Neurosciences Institute enable circuit-level analyses, while single-cell RNA sequencing protocols from Broad Institute and Wellcome Sanger Institute map cell-type specific expression. Clinical imaging studies combining fMRI and PET have been run at Beth Israel Deaconess Medical Center and Charité – Universitätsmedizin Berlin.

Category:Neurotransmitter receptors